ORXOY - Orexo AB (publ)

Other OTC - Other OTC Delayed Price. Currency in USD
5.85
0.00 (0.00%)
At close: 9:30AM EDT
Stock chart is not supported by your current browser
Previous Close5.85
Open5.85
Bid0.00 x 0
Ask0.00 x 0
Day's Range5.85 - 5.85
52 Week Range5.62 - 8.95
Volume300
Avg. Volume60
Market Cap197.842M
Beta (3Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire

    Orexo Signs Partnership Agreement With GAIA to Develop and Commercialize a new Digital Therapy for the Treatment of Opioid Use Disorder

    UPPSALA, Sweden, Aug. 20, 2019 /PRNewswire/ -- Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces it has entered into an exclusive agreement with GAIA AG (GAIA), a global leader in digital therapeutics that successfully launched its first digital health product in 2001, for a new digital therapy (DTx) for the treatment of Opioid Use Disorder (OUD). Orexo will have the exclusive global commercial rights to the product and intends to launch it in the US in 2022, subject to regulatory approval. The medically assisted treatment of OUD requires a complete treatment plan, including effective medication, such as Orexo's commercially available Zubsolv®, and counseling and psychosocial support.

  • CNW Group

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

  • PR Newswire

    Orexo Interim Report Q2 2019

    Improving all fundamentals UPPSALA, Sweden , July 11, 2019 /PRNewswire/ -- Q2 2019 highlights Total net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1 percent when excluding ex-US milestone ...

  • PR Newswire

    Orexo Signs License and Supply Agreement With Mundipharma for Zubsolv® in Australia and New Zealand

    UPPSALA, Sweden, July 10, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces the company has signed an agreement granting Mundipharma Pty Limited (Mundipharma Australia) the exclusive rights to commercialize Orexo's lead product, Zubsolv®, for the treatment of opioid dependence, in Australia and New Zealand. As Mundipharma Australia has supported Orexo to obtain marketing authorization for Zubsolv in Australia it has been a natural step to continue the collaboration.

  • PR Newswire

    Orexo Prepays Part of the Corporate Bond Loan

    UPPSALA, Sweden , July 9, 2019 /PRNewswire/ --Orexo AB (publ.) has resolved to prepay SEK 32.5 million, corresponding to 10 percent, of the unsecured corporate bond loan of in total SEK 325 million, which was issued by the company in November 2017 and which carries a floating interest rate of STIBOR 3m +4.50 percent. The prepayment is made, in accordance with the terms and conditions of the corporate bond loan, at an amount corresponding to 102 percent of the nominal amount of the loan, together with accrued but unpaid interest. "Orexo continues to strengthen the cash position and following the strong first quarter, we decided to take the first possible opportunity to repay a part of the outstanding corporate bond according to the terms.

  • PR Newswire

    Life Science Company Live Investor Conference July 11th

    Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the ...

  • PR Newswire

    Number of Shares and Votes in Orexo

    UPPSALA, Sweden , June 28, 2019 /PRNewswire/ -- The number of shares and votes in Orexo AB (publ.) has changed as a result of the issue and repurchase of 63,000 class C shares as announced on June 12 , ...

  • PR Newswire

    Issue and Repurchase of Class C Shares

    UPPSALA, Sweden , June 12, 2019 /PRNewswire/ -- Orexo AB (publ.) announces that the company has resolved to issue and immediately thereafter repurchase 63,000 class C shares. The shares are issued and ...

  • PR Newswire

    Orexo's Closest Upcoming Presentations at Conferences

    UPPSALA, Sweden , May 17, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will be presenting ...

  • PR Newswire

    Orexo: Interim Report Q1 2019

    Continued strong performance from the US business UPPSALA, Sweden , May 2, 2019 /PRNewswire/ -- Q1 2019 highlights Total net revenues of SEK 174.3 million (139.7), up 24.8 percent Zubsolv® US net revenues ...

  • PR Newswire

    Issues of Shares Following the Vesting of 2016/2019 Incentive Plan

    UPPSALA, Sweden , April 26, 2019 /PRNewswire/ -- The 2016 annual general meeting of Orexo resolved on a long-term incentive plan for senior executives and key employees within the Orexo group ("LTIP ...

  • PR Newswire

    Report from Orexo AB's Annual General Meeting

    The annual general meeting in Orexo AB (publ) on 11 April 2019 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be eight with no deputy board members. Staffan Lindstrand, Martin Nicklasson, Kristina Schauman, David Colpman, Kirsten Detrick and Henrik Kjær Hansen were re-elected as ordinary board members. Martin Nicklasson was re-elected as chairman of the board.